Clinical Pilot Study to Evaluate a New Multi-parameter Neuromonitoring Device in Brain-injured Patients

Exclusion Criteria

• •Known kidney disease, defined as plasma creatinine \> 120 μmol/l
• •Known liver disease, defined as AST \> 200 IU/L
• •Over-active thyroid or benign tumors of the thyroid
• •History of allergic disorders, including allergic reactions, against contrast agents containing iodine, or against ICG
• •Patients which have received one of the following medications before being admitted to ICU: Haloperidol, Meperidine, Methadone, Morphine, Phenobarbital and Rifamycin.
• •Patients with wounds or scars including the front orbital region.
• •Cerebrospinal fluid infection or signs of meningo-encephalitis
• •Anemia (hemoglobin \< 10 g/dl) or Thalassemia
• •Carbon monoxide poisoning
• •Acquired pathological or congenital disorders of the cerebral system, being clinically significant, respectively interfering in the investigator's opinion with the conduct of study
• •Documented history of bleeding, clotting or coagulation disorders
• •Patients who are not suitable for a CT perfusion
• •Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this clinical investigation or will not comply with requirements of the study
• •Any disorder in the investigator's opinion that could interfere with compliance of safety evaluation
• •Pre-existing disability and/or legal representative
• •Patients who are kept lawfully in an institution
• •Participation in another interventional clinical investigation within the last 30 days before start of treatment
• •History of, respectively diagnosis of pregnancy, or breastfeeding patients